Davis Capital Management’s Krystal Biotech KRYS Stock Holding History

Davis Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372	Buy	+1	New	+$299	﹤0.01%	680

Other funds holding KRYS

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS)

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Davis Capital Management's KRYS Position: Q2 2026 in Review

Davis Capital Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1 share worth $372. The stake represents ﹤0.01% of the portfolio and ranks #680 among its holdings.

74 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Davis Capital Management held 1 share of Krystal Biotech worth $372 as of Q2 2026.
Krystal Biotech was a new Davis Capital Management position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #680 holding.
74 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.